CE only topic

Allowed Publications
Exceptions
Don't send to Teambase
Slot System
Featured Buckets
Featured Buckets Admin
Medscape Lead Concept
1679

Gastroenterology Data Trends 2024

Article Type
Changed
Tue, 06/11/2024 - 15:39
Display Headline
Gastroenterology Data Trends 2024

GI&Hepatology News and the American Gastroenterological Association present the 2024 issue of Gastroenterology Data Trends, a special report on hot GI topics told through original infographics and visual storytelling.

In this issue:

 

  1. Eosinophilic Gastrointestinal Diseases: Beyond EoE
    Nirmala Gonsalves, MD, AGAF, FACG
  2. The Changing Face of IBD: Beyond the Western World
    Gilaad G. Kaplan, MD, MPH, AGAF; Paulo Kotze, MD, MS, PhD; Siew C. Ng, MBBS, PhD, AGAF
  3. Role of Non-invasive Biomarkers in the Evaluation and Management of MASLD
    Julia J. Wattacheril, MD, MPH
  4. The Emerging Role of Liquid Biopsy in the Diagnosis and Management of CRC
    David Lieberman, MD, AGAF
  5. Cannabinoids and Digestive Disorders
    Jami A. Kinnucan, MD, AGAF, FACG
  6. AI and Machine Learning in IBD: Promising Applications and Remaining Challenges
    Shirley Cohen-Mekelburg, MD, MS
  7. Simulation-Based Training in Endoscopy: Benefits and Challenges
    Richa Shukla, MD
  8. Fluid Management in Acute Pancreatitis
    Jorge D. Machicado, MD, MPH
Publications
Topics
Sections

GI&Hepatology News and the American Gastroenterological Association present the 2024 issue of Gastroenterology Data Trends, a special report on hot GI topics told through original infographics and visual storytelling.

In this issue:

 

  1. Eosinophilic Gastrointestinal Diseases: Beyond EoE
    Nirmala Gonsalves, MD, AGAF, FACG
  2. The Changing Face of IBD: Beyond the Western World
    Gilaad G. Kaplan, MD, MPH, AGAF; Paulo Kotze, MD, MS, PhD; Siew C. Ng, MBBS, PhD, AGAF
  3. Role of Non-invasive Biomarkers in the Evaluation and Management of MASLD
    Julia J. Wattacheril, MD, MPH
  4. The Emerging Role of Liquid Biopsy in the Diagnosis and Management of CRC
    David Lieberman, MD, AGAF
  5. Cannabinoids and Digestive Disorders
    Jami A. Kinnucan, MD, AGAF, FACG
  6. AI and Machine Learning in IBD: Promising Applications and Remaining Challenges
    Shirley Cohen-Mekelburg, MD, MS
  7. Simulation-Based Training in Endoscopy: Benefits and Challenges
    Richa Shukla, MD
  8. Fluid Management in Acute Pancreatitis
    Jorge D. Machicado, MD, MPH

GI&Hepatology News and the American Gastroenterological Association present the 2024 issue of Gastroenterology Data Trends, a special report on hot GI topics told through original infographics and visual storytelling.

In this issue:

 

  1. Eosinophilic Gastrointestinal Diseases: Beyond EoE
    Nirmala Gonsalves, MD, AGAF, FACG
  2. The Changing Face of IBD: Beyond the Western World
    Gilaad G. Kaplan, MD, MPH, AGAF; Paulo Kotze, MD, MS, PhD; Siew C. Ng, MBBS, PhD, AGAF
  3. Role of Non-invasive Biomarkers in the Evaluation and Management of MASLD
    Julia J. Wattacheril, MD, MPH
  4. The Emerging Role of Liquid Biopsy in the Diagnosis and Management of CRC
    David Lieberman, MD, AGAF
  5. Cannabinoids and Digestive Disorders
    Jami A. Kinnucan, MD, AGAF, FACG
  6. AI and Machine Learning in IBD: Promising Applications and Remaining Challenges
    Shirley Cohen-Mekelburg, MD, MS
  7. Simulation-Based Training in Endoscopy: Benefits and Challenges
    Richa Shukla, MD
  8. Fluid Management in Acute Pancreatitis
    Jorge D. Machicado, MD, MPH
Publications
Publications
Topics
Article Type
Display Headline
Gastroenterology Data Trends 2024
Display Headline
Gastroenterology Data Trends 2024
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Wed, 05/15/2024 - 16:00
Un-Gate On Date
Wed, 05/15/2024 - 16:00
Use ProPublica
CFC Schedule Remove Status
Wed, 05/15/2024 - 16:00
Hide sidebar & use full width
Do not render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article

Gastroenterology Data Trends 2023

Article Type
Changed
Wed, 10/11/2023 - 10:46

GI&Hepatology News and the American Gastroenterological Association present the 2023 issue of Gastroenterology Data Trends, a special report on hot topics in gastroenterology told through original infographics and visual storytelling.

In this issue:

Publications
Topics
Sections

GI&Hepatology News and the American Gastroenterological Association present the 2023 issue of Gastroenterology Data Trends, a special report on hot topics in gastroenterology told through original infographics and visual storytelling.

In this issue:

GI&Hepatology News and the American Gastroenterological Association present the 2023 issue of Gastroenterology Data Trends, a special report on hot topics in gastroenterology told through original infographics and visual storytelling.

In this issue:

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Fri, 09/22/2023 - 11:15
Un-Gate On Date
Fri, 09/22/2023 - 11:15
Use ProPublica
CFC Schedule Remove Status
Fri, 09/22/2023 - 11:15
Hide sidebar & use full width
Do not render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article

Evolving Therapeutic Goals in Crohn’s Disease Management

Article Type
Changed
Thu, 11/10/2022 - 15:39
Display Headline
Evolving Therapeutic Goals in Crohn’s Disease Management
References
  1. Dorrington AM, Selinger CP, Parkes GC, Smith M, Pollok RC, Raine T. The historical role and contemporary use of corticosteroids in inflammatory bowel disease. J Crohns Colitis. 2020;14(9):1316-1329. doi:10.1093/ecco-jcc/jjaa053 
  2. Melsheimer R, Geldhof A, Apaolaza I, Schaible T. Remicade® (infliximab): 20 years of contributions to science and medicine. Biologics. 2019;13:139-178. doi:10.2147/BTT.S207246 
  3. Kumar A, Cole A, Segal J, Smith P, Limdi JK. A review of the therapeutic management of Crohn’s disease. Therap Adv Gastroenterol. 2022;15:17562848221078456. doi:10.1177/17562848221078456 
  4. Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017;390(10114):2779-2789. doi:10.1016/S0140-6736(17)32641-7 
  5. Ungaro RC, Yzet C, Bossuyt P, et al. Deep remission at 1 year prevents progression of early Crohn’s disease. Gastroenterology. 2020;159(1):139-147. doi:10.1053/j.gastro.2020.03.039 
  6. Tsai L, Ma C, Dulai PS, et al. Contemporary risk of surgery in patients with ulcerative colitis and Crohn’s disease: a meta-analysis of population-based cohorts. Clin Gastroenterol Hepatol. 2021;19(10):2031-2045.e11. doi:10.1016/j.cgh.2020.10.039 
  7. Chapman S, Sibelli A, St-Clair Jones A, Forbes A, Chater A, Horne R. Personalised adherence support for maintenance treatment of inflammatory bowel disease: a tailored digital intervention to change adherence-related beliefs and barriers. J Crohns Colitis. 2020;14(10):1394-1404. doi:10.1093/ecco-jcc/jjz034 
  8. Turner D, Ricciuto A, Lewis A, et al; for the International Organization for the Study of IBD. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570-1583. doi:10.1053/j.gastro.2020.12.031 
  9. Rozich JJ, Dulai PS, Fumery M, Sandborn WJ, Singh S. Progression of elderly onset inflammatory bowel diseases: a systematic review and meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2020;18(11):2437-2447.e6. doi:10.1016/j.cgh.2020.02.048 
  10. Dahlhamer JM, Zammitti EP, Ward BW, Wheaton AG, Croft JB. Prevalence of inflammatory bowel disease among adults aged ≥18 years — United States, 2015. MMWR Morb Mortal Wkly Rep. 2016;65(42):1166-1169.doi:10.15585/mmwr.mm6542a3 
  11. M’Koma AE. Inflammatory bowel disease: clinical diagnosis and surgical treatment-overview. Medicina (Kaunas). 2022;58(5):567. doi:10.3390/medicina58050567 
  12. Weissman S, Patel K, Kolli S, et al. Obesity in inflammatory bowel disease is associated with early readmissions characterised by an increased systems and patient-level burden. J Crohns Colitis. 2021;15(11):1807-1815. doi:10.1093/ecco-jcc/jjab088 
  13. Agrawal M, Spencer EA, Colombel JF, Ungaro RC. Approach to the management of recently diagnosed inflammatory bowel disease patients: a user’s guide for adult and pediatric gastroenterologists. Gastroenterology. 2021;161(1):47-65. doi:10.1053/j.gastro.2021.04.063 
  14. Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn’s disease. Gut. 2000;47(4):506-513. doi:10.1136/gut.47.4.506. 
  15. Singh S, Proctor D, Scott FI, Falck-Ytter Y, Feuerstein JD. AGA technical review on the medical management of moderate to severe luminal and perianal fistulizing Crohn’s disease. Gastroenterology. 2021;160(7):2512-2556.e9. doi:10.1053/j.gastro.2021.04.023 
Publications
Topics
References
  1. Dorrington AM, Selinger CP, Parkes GC, Smith M, Pollok RC, Raine T. The historical role and contemporary use of corticosteroids in inflammatory bowel disease. J Crohns Colitis. 2020;14(9):1316-1329. doi:10.1093/ecco-jcc/jjaa053 
  2. Melsheimer R, Geldhof A, Apaolaza I, Schaible T. Remicade® (infliximab): 20 years of contributions to science and medicine. Biologics. 2019;13:139-178. doi:10.2147/BTT.S207246 
  3. Kumar A, Cole A, Segal J, Smith P, Limdi JK. A review of the therapeutic management of Crohn’s disease. Therap Adv Gastroenterol. 2022;15:17562848221078456. doi:10.1177/17562848221078456 
  4. Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017;390(10114):2779-2789. doi:10.1016/S0140-6736(17)32641-7 
  5. Ungaro RC, Yzet C, Bossuyt P, et al. Deep remission at 1 year prevents progression of early Crohn’s disease. Gastroenterology. 2020;159(1):139-147. doi:10.1053/j.gastro.2020.03.039 
  6. Tsai L, Ma C, Dulai PS, et al. Contemporary risk of surgery in patients with ulcerative colitis and Crohn’s disease: a meta-analysis of population-based cohorts. Clin Gastroenterol Hepatol. 2021;19(10):2031-2045.e11. doi:10.1016/j.cgh.2020.10.039 
  7. Chapman S, Sibelli A, St-Clair Jones A, Forbes A, Chater A, Horne R. Personalised adherence support for maintenance treatment of inflammatory bowel disease: a tailored digital intervention to change adherence-related beliefs and barriers. J Crohns Colitis. 2020;14(10):1394-1404. doi:10.1093/ecco-jcc/jjz034 
  8. Turner D, Ricciuto A, Lewis A, et al; for the International Organization for the Study of IBD. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570-1583. doi:10.1053/j.gastro.2020.12.031 
  9. Rozich JJ, Dulai PS, Fumery M, Sandborn WJ, Singh S. Progression of elderly onset inflammatory bowel diseases: a systematic review and meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2020;18(11):2437-2447.e6. doi:10.1016/j.cgh.2020.02.048 
  10. Dahlhamer JM, Zammitti EP, Ward BW, Wheaton AG, Croft JB. Prevalence of inflammatory bowel disease among adults aged ≥18 years — United States, 2015. MMWR Morb Mortal Wkly Rep. 2016;65(42):1166-1169.doi:10.15585/mmwr.mm6542a3 
  11. M’Koma AE. Inflammatory bowel disease: clinical diagnosis and surgical treatment-overview. Medicina (Kaunas). 2022;58(5):567. doi:10.3390/medicina58050567 
  12. Weissman S, Patel K, Kolli S, et al. Obesity in inflammatory bowel disease is associated with early readmissions characterised by an increased systems and patient-level burden. J Crohns Colitis. 2021;15(11):1807-1815. doi:10.1093/ecco-jcc/jjab088 
  13. Agrawal M, Spencer EA, Colombel JF, Ungaro RC. Approach to the management of recently diagnosed inflammatory bowel disease patients: a user’s guide for adult and pediatric gastroenterologists. Gastroenterology. 2021;161(1):47-65. doi:10.1053/j.gastro.2021.04.063 
  14. Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn’s disease. Gut. 2000;47(4):506-513. doi:10.1136/gut.47.4.506. 
  15. Singh S, Proctor D, Scott FI, Falck-Ytter Y, Feuerstein JD. AGA technical review on the medical management of moderate to severe luminal and perianal fistulizing Crohn’s disease. Gastroenterology. 2021;160(7):2512-2556.e9. doi:10.1053/j.gastro.2021.04.023 
References
  1. Dorrington AM, Selinger CP, Parkes GC, Smith M, Pollok RC, Raine T. The historical role and contemporary use of corticosteroids in inflammatory bowel disease. J Crohns Colitis. 2020;14(9):1316-1329. doi:10.1093/ecco-jcc/jjaa053 
  2. Melsheimer R, Geldhof A, Apaolaza I, Schaible T. Remicade® (infliximab): 20 years of contributions to science and medicine. Biologics. 2019;13:139-178. doi:10.2147/BTT.S207246 
  3. Kumar A, Cole A, Segal J, Smith P, Limdi JK. A review of the therapeutic management of Crohn’s disease. Therap Adv Gastroenterol. 2022;15:17562848221078456. doi:10.1177/17562848221078456 
  4. Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017;390(10114):2779-2789. doi:10.1016/S0140-6736(17)32641-7 
  5. Ungaro RC, Yzet C, Bossuyt P, et al. Deep remission at 1 year prevents progression of early Crohn’s disease. Gastroenterology. 2020;159(1):139-147. doi:10.1053/j.gastro.2020.03.039 
  6. Tsai L, Ma C, Dulai PS, et al. Contemporary risk of surgery in patients with ulcerative colitis and Crohn’s disease: a meta-analysis of population-based cohorts. Clin Gastroenterol Hepatol. 2021;19(10):2031-2045.e11. doi:10.1016/j.cgh.2020.10.039 
  7. Chapman S, Sibelli A, St-Clair Jones A, Forbes A, Chater A, Horne R. Personalised adherence support for maintenance treatment of inflammatory bowel disease: a tailored digital intervention to change adherence-related beliefs and barriers. J Crohns Colitis. 2020;14(10):1394-1404. doi:10.1093/ecco-jcc/jjz034 
  8. Turner D, Ricciuto A, Lewis A, et al; for the International Organization for the Study of IBD. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570-1583. doi:10.1053/j.gastro.2020.12.031 
  9. Rozich JJ, Dulai PS, Fumery M, Sandborn WJ, Singh S. Progression of elderly onset inflammatory bowel diseases: a systematic review and meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2020;18(11):2437-2447.e6. doi:10.1016/j.cgh.2020.02.048 
  10. Dahlhamer JM, Zammitti EP, Ward BW, Wheaton AG, Croft JB. Prevalence of inflammatory bowel disease among adults aged ≥18 years — United States, 2015. MMWR Morb Mortal Wkly Rep. 2016;65(42):1166-1169.doi:10.15585/mmwr.mm6542a3 
  11. M’Koma AE. Inflammatory bowel disease: clinical diagnosis and surgical treatment-overview. Medicina (Kaunas). 2022;58(5):567. doi:10.3390/medicina58050567 
  12. Weissman S, Patel K, Kolli S, et al. Obesity in inflammatory bowel disease is associated with early readmissions characterised by an increased systems and patient-level burden. J Crohns Colitis. 2021;15(11):1807-1815. doi:10.1093/ecco-jcc/jjab088 
  13. Agrawal M, Spencer EA, Colombel JF, Ungaro RC. Approach to the management of recently diagnosed inflammatory bowel disease patients: a user’s guide for adult and pediatric gastroenterologists. Gastroenterology. 2021;161(1):47-65. doi:10.1053/j.gastro.2021.04.063 
  14. Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn’s disease. Gut. 2000;47(4):506-513. doi:10.1136/gut.47.4.506. 
  15. Singh S, Proctor D, Scott FI, Falck-Ytter Y, Feuerstein JD. AGA technical review on the medical management of moderate to severe luminal and perianal fistulizing Crohn’s disease. Gastroenterology. 2021;160(7):2512-2556.e9. doi:10.1053/j.gastro.2021.04.023 
Publications
Publications
Topics
Article Type
Display Headline
Evolving Therapeutic Goals in Crohn’s Disease Management
Display Headline
Evolving Therapeutic Goals in Crohn’s Disease Management
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Fri, 10/21/2022 - 16:15
Un-Gate On Date
Fri, 10/21/2022 - 16:15
Use ProPublica
CFC Schedule Remove Status
Fri, 10/21/2022 - 16:15
Hide sidebar & use full width
Do not render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Article Slideshow Optional Introduction

Over the last 2 decades, the armamentarium for Crohn’s disease has expanded with the introduction of targeted biologic therapies. Beginning with the approval of infliximab by the FDA in 1998, the treatment options for Crohn’s disease have greatly improved.1 Although steroids are still prescribed too frequently, novel therapies now can limit the use of steroids in these patients.2 In addition to anti-tumor necrosis factor alpha (anti-TNF-alpha) biologics, new therapies that target  integrins, interleukin (IL)-12/23, and IL-23 have also demonstrated efficacy in inducing and maintaining clinical and endoscopic remission of Crohn’s disease.3

Other studies have shown what consistent therapeutic control can do for patients with Crohn’s disease.  Effective therapies can maintain remission and even halt progression to complications if the disease is  identified and treated in its early stages.4,5 Since the early 2000s, a significant drop in risk for surgery among patients with Crohn’s has also been observed because of improved management.6 Of course, patient acceptance and adherence to their regimens is critical. Patients who understand they need on-time treatment, have access to appropriate treatment, and get their questions answered in a timely fashion will be more adherent than those who do not.7 A key advance in management is the adoption of a treat-to-target strategy in which the therapeutic goal has evolved beyond symptom improvement to include the achievement of objective metrics of remission, in particular endoscopic healing.8

These successes are juxtaposed against Crohn’s disease incidence and prevalence figures, which are rising mostly everywhere.9 In 1999, 1.8 million adults in the United States had the disease; in 2015, that figure was 3.1 million.10 Crohn’s disease, usually considered a younger adult disease, is also growing in incidence in adults older than 60 years.9 While the underlying causes of this disease are not well understood, its development involves environmental factors, dysregulated innate and adaptive immune systems, and genetic predisposition.11 With increasing investigation focused on understanding the disease’s initial triggering events and how environmental factors, like diet, affect Crohn’s disease, there is hope these research findings will lead to better management and treatment options.12

Slide
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Slide Media